Drug intelligence / Profile preview

verpacamide a

Development stage: Unknown
Modality: Peptides, Small Molecules

Overview

Verpacamide A is an experimental small molecule classified as an alpha amino acid derivative, specifically a cyclic dipeptide composed of L-arginine and L-proline. Its chemical formula is C11H19N5O2, and it has been referenced as "cyclo-(L-arginine-L-proline) inhibitor." There are no approved indications or clinical trials reported for this compound. The mechanism of action and therapeutic applications remain uncharacterized in the available literature[1][2][3].

Other names: cyclo-(l-arginine-l-proline) inhibitor

Beyond the preview

Go deeper on verpacamide a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on verpacamide a.

Explore the full profile